TScan Therapeutics TCRX 深 沪
等待开盘 11-13 09:30:00 美东时间
0.168
-0.018
-9.48%
华盛通- 最 高0.183
- 今 开0.183
- 成交量 71.45万股
- 最 低 0.1603
- 昨 收 0.1856
- 总市值 1138.69万
- 52周最高 1.47
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 0.1603
- 委 比 33.33%
- 总股本 6777.92万
- 历史最高 14.71
- 量 比 1.44
- 振 幅 12.23%
- 历史最低 0.1603
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TScan Therapeutics Q3 EPS $(0.25) Misses $(0.19) Estimate, Sales $586.000K Beat $459.000K Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 10.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $586.000 ...
11-12 20:14
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
<p>TScan Therapeutics announced a strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumors, advancing PRAME- and MAGE-A4-targeted candidates through IND-enabling studies with the goal of dosing the first patient by Q4 2027. The company paused enrollment in the Phase 3 ALLOHA-2™ study of TSC-101 due to capital constraints and is seeking strategic partners. Cash and cash equivalents of $73.0 million are expected t...
11-12 12:00
TScan Therapeutics Announces Executive Departures Amid Reorganization
An announcement from TScan Therapeutics ( ($TCRX) ) is now available. TScan The...
10-01 05:33
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%. The clinical-stage biotechnology company is shifting capital toward its lead oncology programs while pau...
09-02 23:36
TScan Therapeutics shares are trading lower after the company announced it paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial. Also, the company will reduce its workforce by 75%.
TScan Therapeutics shares are trading lower after the company announced it paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial. Also, the company will reduce its workforce by 75%.
09-02 20:53
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics announced strategic reorganization to focus on its in vivo solid tumor program, advancing two TCR-T candidates to IND studies with Phase 1 development planned for Q4 2027. The company paused its Phase 3 ALLOHA-2™ study of TSC-101 due to capital constraints, while Cohort C of the Phase 1 ALLOHA™ study showed 100% complete donor chimerism in 13 patients. TScan reduced its workforce by ~75% to concentrate resources on solid tumors...
09-02 11:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
08-12 23:25
